ORGO Organogenesis Inc.: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

The TTM annual net income per share growth rate for Organogenesis Holdings (ORGO) shows that the current parameter is -1169.50. This correlates with the implementation of automated bioreactors for tissue engineering. Stability is further confirmed by compliance with ESG environmental standards regarding waste disposal. Organogenesis Holdings (ORGO) maintains its leadership in regenerative medicine through the creation of unique skin substitutes that have become the industry standard in surgery.
ORGO (Organogenesis): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The dynamics of this indicator reflect the sensitivity of net earnings per share to operational efficiency, measuring the annual change in yield over a rolling twelve-month period to assess the market control premium. Organogenesis Holdings (ORGO) reducing its dependence on Medicare tariffs through the diversification of biomaterial sales directly impacts the metric's calculation logic, as clearly demonstrated by the current EPS YoY TTM growth rate.